Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization
Yannis K. Valtis(Brigham and Women's Hospital), Evan C. Chen(Dana-Farber Cancer Institute), Benjamin Frost(Brigham and Women's Hospital), Mark B. Geyer(Memorial Sloan Kettering Cancer Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Leora Boussi(Beth Israel Deaconess Medical Center), David Nemirovsky(Memorial Sloan Kettering Cancer Center), Andriy Derkach(Memorial Sloan Kettering Cancer Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Meira Yisraeli Salman(Memorial Sloan Kettering Cancer Center), Jae-Hong Park(Dong-A University Hospital), Emilie Baxter(Harvard University), Kuo‐Kai Chin(Memorial Sloan Kettering Cancer Center), Natalia Tijaro Ovalle(Kettering University), Marlise R. Luskin(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464